Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS Phase I: 1. To define the maximum tolerated dose (MTD) of OSI-774 (erlotinib;TarcevaTM) in combination with CCI-779 (temsirolimus) in patients with recurrent malignant glioma who are not taking enzyme-inducing anti-epileptic drugs (EIAEDs). 2. To characterize the safety profile of OSI-774 (erlotinib) and CCI-779 (temsirolimus). 3. To characterize the pharmacokinetics of OSI-774 (erlotinib) and CCI-779 (temsirolimus). Phase II: Primary Aim: 1. To determine the efficacy of OSI-774 (erlotinib) and CCI-779 (temsirolimus) in patients with recurrent malignant glioma as measured by 6-month progression-free survival. Secondary Aims: 1. Overall progression-free survival 2. Response Exploratory Aims: 1. To explore the association of response to treatment to the molecular phenotype of the tumor. 2. Determine whether OSI-774 (erlotinib) and CCI-779 (temsirolimus) inhibits EGFR and mTOR and the PI3K-AKT-mTOR and RAS-ERK signaling pathways in tumor specimens taken from malignant glioma patients undergoing surgery. 3. Tumor concentration of OSI-774 (erlotinib) and CCI-779 (temsirolimus).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000865-37
Application #
8167082
Study Section
Special Emphasis Panel (ZRR1-CR-4 (01))
Project Start
2009-12-01
Project End
2010-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
37
Fiscal Year
2010
Total Cost
$659
Indirect Cost

  Institution

Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095

  Publications

Ellsworth, G B; Lensing, S Y; Ogilvie, C B et al. (2018) A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men. Papillomavirus Res 6:11-14
Goldman, Noreen; Glei, Dana A; Weinstein, Maxine (2018) Declining mental health among disadvantaged Americans. Proc Natl Acad Sci U S A 115:7290-7295
Dean, Andy C; Morales, Angelica M; Hellemann, Gerhard et al. (2018) Cognitive deficit in methamphetamine users relative to childhood academic performance: link to cortical thickness. Neuropsychopharmacology 43:1745-1752
Nersesian, Paula V; Han, Hae-Ra; Yenokyan, Gayane et al. (2018) Loneliness in middle age and biomarkers of systemic inflammation: Findings from Midlife in the United States. Soc Sci Med 209:174-181
Glei, Dana A; Goldman, Noreen; Ryff, Carol D et al. (2018) Physical Function in U.S. Older Adults Compared With Other Populations: A Multinational Study. J Aging Health :898264318759378
Stephan, Yannick; Sutin, Angelina R; Bayard, Sophie et al. (2018) Personality and sleep quality: Evidence from four prospective studies. Health Psychol 37:271-281
Green, Shulamite A; Hernandez, Leanna M; Bowman, Hilary C et al. (2018) Sensory over-responsivity and social cognition in ASD: Effects of aversive sensory stimuli and attentional modulation on neural responses to social cues. Dev Cogn Neurosci 29:127-139
Tsenkova, Vera K; Lee, Chioun; Boylan, Jennifer Morozink (2017) Childhood Socioeconomic Disadvantage, Occupational, Leisure-Time, and Household Physical Activity, and Diabetes in Adulthood. J Phys Act Health 14:766-772
Schwartz, Joseph A; Portnoy, Jill (2017) Lower catecholamine activity is associated with greater levels of anger in adults. Int J Psychophysiol 120:33-41
Ringman, John M; Casado, Maria; Van Berlo, Victoria et al. (2017) A novel PSEN1 (S230N) mutation causing early-onset Alzheimer's Disease associated with prosopagnosia, hoarding, and Parkinsonism. Neurosci Lett 657:11-15

Showing the most recent 10 out of 1085 publications